Shorter antifungal treatment for yeast bloodstream infection in children
Part of Infections clinical trials.
This trial compares shorter vs longer treatment for children with an uncomplicated yeast (Candida) bloodstream infection once blood cultures are clear. It may help reduce medicine exposure while keeping the infection under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is older than 120 days when the first negative blood culture happens
- Blood tests showed Candida in the bloodstream, and later blood tests turned negative
- Your child started a specific antifungal medicine (like caspofungin, micafungin, anidulafungin, or rezafungin) and stayed on it without gaps
- After the infection was identified, your care team confirmed it stayed cleared before starting the study
- Your child has either improved or met the study’s definition of clinical response by the time they are randomized
- There was no suspicion (and no scans needed/ordered) that the yeast spread to other organs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a shorter course of the antifungal drug caspofungin (7 days instead of the usual 14) is just as effective for people with uncomplicated candidemia, a bloodstream infection caused by Candida yeast. If you've already had 7 days of caspofungin and your blood is clear of Candida, you might be able to stop treatment sooner.
This study looks at patients in the intensive care unit who have a new infection with Candida (a type of fungus) despite taking strong antibiotics. It aims to better understand and diagnose these serious infections.
This Phase 3 trial tests fosmanogepix to treat adults with candidemia (Candida in the bloodstream) and/or invasive candidiasis (a deep Candida infection). It looks at whether the medicine is effective and safe, and whether it helps the infection improve when doctors also manage the infection source.
This study tests whether shorter courses of antibiotics are as effective as longer ones for children hospitalized with pneumonia, skin infections, or urinary tract infections. It may help children get back to normal faster and reduce side effects.
This trial compares a shorter course of antifungal medicine to a longer one for people who have candidemia (a yeast infection in the blood). It looks at whether treating for a shorter time is just as safe and effective, which could mean fewer side effects and a quicker recovery.
This trial compares two lengths of antifungal treatment for a bloodstream yeast infection that has not spread: 7 days versus the standard 14 days. The goal is to see if a shorter course works just as well with fewer side effects.
Hear when a new Invasive Candidiasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.